We are monitoring the impact of COVID-19 on Europe Ophthalmology Therapeutics Market Get in touch with us for detailed analysis Know More
Pulished Date February, 2020
ID: 1045
Share on
Share on

Europe Ophthalmology Therapeutics Market Research Report – Segmented By Indication, End User, Country (UK, France, Spain, Germany, Italy, Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe) - Industry Analysis, Size, Share, Growth, Trends, Forecast (2019 - 2024)

Pulished: February, 2020
ID: 1045
Pages: 145

Europe Ophthalmology Therapeutics Market was worth USD 6.44 billion in 2019 and estimated to be growing at a CAGR of 6.9%, to reach USD 8.98 billion by 2024.

The market is showing evident potential in the mentioned forecast period. Ophthalmology deals with the treatment of eye defects and diseases. Age-related macular degeneration is the major cause of visual loss in adults in industrialized countries, other conditions associated with vision loss include cataract, diabetic retinopathy, and glaucoma along with a low vision.

There are around 25 million people with visual impairment in Europe. It is estimated that more than 70 million people have eye diseases that are in the early stages which if left untreated may lead to severe impairment.

Europe Ophthalmology Therapeutics is driven by the increasing incidence of vision impairment. Advancements in technology in the field of medicine are also playing a key role in the growth of the market. The growing geriatric population across the continent along with an increase in disposable income of the people are some of the factors adding up to the market growth.

However, stringent regulatory framework and unclear reimbursement policies are also acting as hurdles for market growth. Lack of awareness about various diseases associated with ophthalmology is also a major restraint hindering the market growth.

This research report segmented and sub-segmented the Market into the following categories:

  • By Indication: Glaucoma, Dry Eye Syndrome, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration, Macular Edema and Allergic Conjunctivitis.
  • By End User: Hospitals, Eye Clinics, Diagnostic Centres and Patients.
  • By Country: UK, France, Spain, Germany, Italy,  Russia, Sweden, Denmark, Switzerland, Netherlands, Turkey, Czech Republic and Rest of Europe

Geographically, Within Europe, Germany is the largest market for Ophthalmology Therapeutics Glaucoma is the largest indication segment accounting for a share of approximately 31% followed by AMD with a share of XX%.

Companies playing a leading role in the European Ophthalmology Therapeutics Market are Pfizer Inc., Allergan Inc., Alcon Inc., Merck & co. Inc., Roche Valeant, Regeneron, Santen, Bayer, Senju, Lpath and Eye Gate Pharmaceuticals.

1.Introduction                                  

                1.1 Market Definition                    

                1.2 Study Deliverables                  

                1.3 Base Currency, Base Year and Forecast Periods                           

                1.4 General Study Assumptions                

2. Research Methodology                                           

                2.1 Introduction                              

                2.2 Research Phases                      

                                2.2.1 Secondary Research            

                                2.2.2 Primary Research 

                                2.2.3 Econometric Modelling     

                                2.2.4 Expert Validation  

                2.3 Analysis Design                         

                2.4 Study Timeline                          

3. Overview                                      

                3.1 Executive Summary                

                3.2 Key Inferences                         

4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)                                      

                4.1 Market Drivers                          

                4.2 Market Restraints                    

                4.3 Key Challenges                         

                4.4 Current Opportunities in the Market               

5. Market Segmentation                                              

                5.1 By Indication                              

                                5.1.1 Glaucoma

                                5.1.2 Dry Eye Syndrome

                                5.1.3 Diabetic Retinopathy         

                                5.1.4 Retinal Vein Occlusion        

                                5.1.5 Age-Related Macular Degeneration (AMD)

                                5.1.6 Macular Edema    

                                5.1.7 Allergic Conjunctivitis         

                5.2 By End User               

                                5.2.1 Hospitals  

                                5.2.2 Eye Clinics

                                5.2.3 Diagnostic Centers              

                                5.2.4 Patients   

6. Geographical Analysis                                              

                6.1 Introduction                              

                6.2 U.K                

                6.3 Spain                             

                6.4 Germany                     

                6.5 Italy                               

                6.6 France                          

7. Pipeline Product Analysis                                        

                7.1 Overview                    

                7.2 Pipeline Development Landscape                     

                7.3 Molecular Targets in the Pipeline                      

                7.4 Clinical Trials                              

                                7.4.1 Failure Rate by Stage of Development, Indication, Molecule Type and Molecular Target       

                                7.4.2 Clinical Trial Duration by Stage of Development, Indication, Molecule Type and Molecular Target                

                                7.4.3 Clinical Trial Size by Stage of Development, Indication, Molecule Type and Molecular Target               

8.Strategic Analysis                                        

                8.1 PESTLE analysis                         

                                8.1.1 Political     

                                8.1.2 Economic 

                                8.1.3 Social         

                                8.1.4 Technological         

                                8.1.5 Legal          

                                8.1.6 Environmental      

                8.2 Porter’s Five analysis                              

                                8.2.1 Bargaining Power of Suppliers        

                                8.2.2 Bargaining Power of Consumers    

                                8.2.3 Threat of New Entrants     

                                8.2.4 Threat of Substitute Products and Services

                                8.2.5 Competitive Rivalry within the Industry      

9.Market Leaders' Analysis                                          

                9.1 Allergan, Inc.                              

                                9.1.1 Overview

                                9.1.2 Product Analysis   

                                9.1.3 Financial analysis  

                                9.1.4 Recent Developments       

                                9.1.5 SWOT analysis       

                                9.1.6 Analyst View          

                9.2 Merck & Co Inc                         

                9.3 Pfizer                            

                9.4 Roche                           

                9.5 Novartis (Alcon)                       

                9.6 Valeant                        

                9.7 Regeneron                 

                9.8 Santen                         

                9.9 Bayer                            

                9.10 Senju                          

                9.11 Lpath                          

                9.12 Eye Gate Pharmaceuticals                 

10.Competitive Landscape                                          

                10.1 Market share analysis                          

                10.2 Merger and Acquisition Analysis                     

                10.3 Agreements, collaborations and Joint Ventures                       

                10.4 New Product Launches                       

11.Market Outlook & Investment Opportunities                               

Appendix                                           

                a) List of Tables                

                b) List of Figures                              

  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. Europe Ophthalmology Therapeutics Market By Region, From 2019 - 2024 (USD Billion)
  2. Europe Ophthalmology Therapeutics Market By Indication, From 2019 - 2024 (USD Billion)
  3. Europe Glaucoma Market By Region, From 2019 - 2024 (USD Billion)
  4. Europe Dry Eye Syndrome Market By Region, From 2019 - 2024 (USD Billion)
  5. Europe Diabetic Retinopathy Market By Region, From 2019 - 2024 (USD Billion)
  6. Europe Retinal Vein Occlusion Market By Region, From 2019 - 2024 (USD Billion)
  7. Europe Age-Related Macular Degeneration (AMD) Market By Region, From 2019 - 2024 (USD Billion)
  8. Europe Macular Edema Market By Region, From 2019 - 2024 (USD Billion)
  9. Europe Allergic Conjunctivitis Market By Region, From 2019 - 2024 (USD Billion)
  10. Europe Ophthalmology Therapeutics Market By End-User, From 2019 - 2024 (USD Billion)
  11. Europe Hospitals Market By Region, From 2019 - 2024 (USD Billion)
  12. Europe Eye Clinics Market By Region, From 2019 - 2024 (USD Billion)
  13. Europe Diagnostic Centers Market By Region, From 2019 - 2024 (USD Billion)
  14. Europe Patients Market By Region, From 2019 - 2024 (USD Billion)
  15. U.K Ophthalmology Therapeutics Market By Indication, From 2019 - 2024 (USD Billion)
  16. U.K Ophthalmology Therapeutics Market By End-User, From 2019 - 2024 (USD Billion)
  17. Spain Ophthalmology Therapeutics Market By Indication, From 2019 - 2024 (USD Billion)
  18. Spain Ophthalmology Therapeutics Market By End-User, From 2019 - 2024 (USD Billion)
  19. Germany Ophthalmology Therapeutics Market By Indication, From 2019 - 2024 (USD Billion)
  20. Germany Ophthalmology Therapeutics Market By End-User, From 2019 - 2024 (USD Billion)
  21. Italy Ophthalmology Therapeutics Market By Indication, From 2019 - 2024 (USD Billion)
  22. Italy Ophthalmology Therapeutics Market By End-User, From 2019 - 2024 (USD Billion)
  23. France Ophthalmology Therapeutics Market By Indication, From 2019 - 2024 (USD Billion)
  24. France Ophthalmology Therapeutics Market By End-User, From 2019 - 2024 (USD Billion)

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample